Exemestan in breast cancer treatment Review article
Article Sidebar
Main Article Content
Abstract
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials results indicates aromatase inhibitors as a valuable alternative for postmenopausal patients. Exemestane is a steroid aromatase inhibitor with effectiveness proven in clinical trials discussed in this article.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Beatson G.W.: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 148(3802): 104-107.
4. Zilembo N., Noberasco C., Bajetta E., Martinetti A., Mariani L., Orefici S.: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer 1995; 72: 1007-1012.
5. Spinelli R., Jannuzzo M.G., Poggesi I., Frevola L., Broutin F., Cicioni P.: Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur. J. Cancer 1999; 35(suppl. 4): S295.
6. Coombes R.C., Hall E., Gibson L.J. et al. for the Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004; 350: 1081-92.
7. Coombes R.C., Kilburn L.S., Snowdon C.F. et al.: Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369(9561): 559.
8. van de Velde C.J.H., Rea D., Seynaeve C. et al.: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377: 321-31.
9. Goss P.E., Ingle J.N., Chapman J.A. et al.: Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium; 8–12 grudnia 2010, San Antonio (TX). Abstract S1–1.
10. Kaufmann M., Bajetta E., Dirix L.Y. et al.: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial – The Exemestane Study Group. J. Clin. Oncol. 2000; 18: 1399-1411.
11. Chia S., Gradishar W., Mauriac L. et al.: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 2008 Apr 1; 26(10): 1664-70.
12. Semiglazov V., Kletsel A., Semiglazov E. et al.: Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2,T3N0-1,T4N0M0) (ASCO). J. Clin. Oncol. 2005; 23: 530.
13. Baselga J., Campone M., Piccart M. et al.: Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 366: 520-529.
14. Baselga J.: Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. 2011 European Multidisciplinary Cancer Congress; 26 września 2011; abstract 9LBA.